Last updated on April 18, 2014 at 21:21 EDT

Strong Endorsements cited for MedQIA – Imaging CRO’s Novel Bone Scan Scoring System at the ASCO 2012 Annual Meeting

July 3, 2012

LOS ANGELES, July 3, 2012 /PRNewswire/ — MedQIA has developed a bone scan analysis package within our 510 (k) – cleared Imaging Biomarker Information System (IBIS). It includes a new automated technique for detecting lesions on bone scans that involves intensity normalization, thresholding, and connected-component analysis. The system calculates quantitative metrics for assessing disease burden and treatment response including total Bone Scan Lesion Area (BSLA), Bone Scan Lesion Intensity (BSLI), and Bone Scan Lesion Count (BSLC).

    1) During the breakout Oral Session for
     Prostate Cancer,  Karim Fizazi, MD,
     Ph.D., of the Institute Gustavo Roussy
     stated the following:

    "I would like to emphasize that we now have
     a new computer assisted detection system
     available for response in bone scan and I
     think this is a very important landmark
     for research in prostate cancer, because
     it is so difficult to measure response and
     progression in that disease."

    2) During the Poster Discussion Session
     for Genitourinary (Prostate ) Cancer,
     Ulka Vaishampayan, MD,  stated:

    "This methodology should be encouraged for
     future evaluation of novel agents since it
     lets you keep the efficacy without
     compromising and continuing to reduce

This automated system allows for reproducible quantification of metastases in bone scans and reliable interpatient and intrapatient comparison. It has been established as an objective measurement of treatment effects. Trials are ongoing that include validation against other clinically relevant outcome measures.

About MedQIA

MedQIA is a full service Imaging CRO that specializes in Computer Vision systems for automated image analysis and measurement. Computer-calculated imaging biomarkers are more accurate, sensitive, and reproducible than manual human measurements. This results in shorter trials with fewer subjects and enables adaptive study designs. What sets us apart is our ability to develop and validate novel imaging biomarkers for use in global, regulated clinical trials.

MedQIA provides a full range of core laboratory services and handles all aspects of your clinical trial from planning to completion.

We offer our services worldwide with regional offices in the US, Australasia and Europe.

For more information please visit our website at www.medqia.com

Contact Information: Juliette Bridges, MS, MBA – Business Development Manager: jbridges@medqia.com 1-888-963-3742


Source: PR Newswire